Anti-NO Tyrosine polyclonal antibody

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have completely reinvented therapeutic care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring an activating EGFR mutation (Ex19del or L858R). The survival benefit with the third-generation EGFR-TKI osimertinib as compared with the first-generation agents gefitinib and erlotinib(1) has cemented its role in the current therapeutic landscape in patients with metastatic disease. However, no such advances have been seen over the past two decades for localized resectable disease. After complete resection, a small but significant survival benefit (5% at 5 years, corresponding to an 11% reduction in the risk of death) . . .

The application of anticancer drugs during pregnancy is associated with placenta-related adverse pregnancy outcomes. Therefore, it is important to study placental toxicity of anticancer drugs. The aim of this study was to compare effects on viability and steroidogenesis in placental tissue explants and trophoblast cell lines. Third trimester placental tissue explants were exposed for 72 h (culture day 4-7) to a concentration range of doxorubicin, paclitaxel, cisplatin, carboplatin, crizotinib, gefitinib, imatinib, or sunitinib. JEG-3, undifferentiated BeWo, and syncytialised BeWo cells were exposed for 48 h to the same drugs and concentrations. After exposure, tissue and cell viability were assessed and progesterone and estrone levels were quantified in culture medium. Apart from paclitaxel, all compounds affected both cell and tissue viability at clinically relevant concentrations. Paclitaxel affected explant viability moderately, while it reduced cell viability by 50% or more in all cell lines, at 3-10 nM. Doxorubicin (1 mu M) reduced viability in explants to 83 +/- 7% of control values, whereas it fully inhibited viability in all cell types. Interference with steroid release in explants was difficult to study due to large variability in measurements, but syncytialised BeWo cells proved suitable for this purpose. We found that 1 mu M sunitinib reduced progesterone release to 76 +/- 6% of control values, without affecting cell viability. While we observed differences between the models for paclitaxel and doxorubicin, most anticancer drugs affected viability significantly in both placental explants and trophoblast cell lines. Taken together, the placenta should be recognized as a potential target organ for toxicity of anticancer drugs.